Drug Trial Radar · NCT06018337
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
541
Actual
Start
Jan 18, 2024
Primary completion
Aug 12, 2026
Study completion Aug 2028
Sponsor
- Lead sponsor
- DualityBio Inc.Industry
- Sponsor type
- Industry
- Collaborators
- BioNTech SE
- First posted
- Aug 30, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to assess the efficacy of DB-1303/BNT323 compared with investigator's choice chemotherapy in terms of progression-free survival (PFS) by blinded independent central review (BICR) in the HR+, HER2-low (immunohistochemistry \[IHC\]2+/in situ hybridization \[ISH\]- and IHC 1+) population.
Conditions
- Metastatic Breast Cancer
Interventions
DB-1303/BNT323Drug
IV
CapecitabineDrug
Oral
PaclitaxelDrug
IV
Nab-paclitaxelDrug
IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS) in the HR+, HER2-low populationTime frame: Up to approximately 51 months
Locations
258 sites in 17 countries. Site status is shown where the registry gives one.
Research Site 1141-0
Tucson, Arizona
Research Site 1114-0
Fullerton, California
Research Site 1107-0
Los Angeles, California
Research Site 1118-0
Orange, California
Research Site 1143-0
Sacramento, California
Research Site 1132-0
Santa Barbara, California
Research Site 1137-0
Aurora, Colorado
Research Site 1129-0
Lone Tree, Colorado
Research Site 1154-0
Jacksonville, Florida
Research Site 1145-0
Miami, Florida
Research Site 1150-0
Orange City, Florida
Research Site 1125-0
Palm Bay, Florida
Research Site 1155-0
Athens, Georgia
Research Site 1110-0
Savannah, Georgia
Research Site 1147-0
Chicago, Illinois
Research Site 1124-0
Chicago Ridge, Illinois
Research Site 1152-0
Fort Wayne, Indiana
Research Site 1106-0
Merriam, Kansas
Research Site 1104-0
Louisville, Kentucky
Research Site 1122-0
Silver Spring, Maryland
Research Site 1109-0
Kansas City, Missouri
Research Site 1158-0
Camden, New Jersey
Research Site 1111-0
Florham Park, New Jersey
Research Site 1157-0
Sante Fe, New Mexico
Research Site 1148-0
Staten Island, New York
Research Site 1105-0
Westbury, New York
Research Site 1144-0
Chapel Hil, North Carolina
Research Site 1138-0
Akron, Ohio
Research Site 1160-0
Cincinnati, Ohio
Research Site 1133-0
Eugene, Oregon
Research Site 1126-0
Tigard, Oregon
Research Site 1134-0
Broomall, Pennsylvania
Research Site 1123-0
Horsham, Pennsylvania
Research Site 1149-0
Knoxville, Tennessee
Research Site 1102-0
Nashville, Tennessee
Research Site 1159-0
Nashville, Tennessee
Research Site 1101-0
Dallas, Texas
Research Site 1116-0
Denison, Texas
Research Site 1115-0
Houston, Texas
Research Site 1117-0
San Antonio, Texas
Showing 40 of 258 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.